Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of congenital FXIII A-subunit deficiency (confirmed by genotyping at screening visit)~* Treatment with regular FXIII replacement therapy initiated at least 6 months prior to screening and one of the following : a documented history of at least one 1 treatment-requiring bleeding episode prior to initiation of regular replacement therapy or a documented family history of FXIII congenital deficiency (only for subjects on regular replacement therapy prior to screening)~* Documented history of at least two 2 bleeding episodes requiring treatment with FXIII containing blood products within the last 12 months prior to screening (only for subjects receiving on-demand treatment prior to screening)~Exclusion Criteria:~* Known neutralizing antibodies (inhibitors) towards FXIII~* Any known congenital or acquired coagulation disorder other than congenital FXIII deficiency~* Documented history of at least 2 treatment-requiring bleeding episodes per year during previous regular replacement therapy with FXIII containing blood products (fresh frozen plasma (FFP), plasma-derived FXIII (pd FXIII) and cryoprecipitate)~* Known or suspected allergy to trial product(s) or related products~* Planned major surgery during the trial period. Catheter, ports and dental extractions do not count as surgeries and will not exclude the subject~* Renal insufficiency defined as current dialysis therapy~* Any history of confirmed venous or arterial thrombo-embolic events

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- rFXIII (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).